🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. Ceritinib (LDK378)

    Novartis Pharmaceuticals

    Tumors With Aberrations in ALK

    phase 2 small molecule terminated

    1 trial

  3. DANAZOL , -, -, -, ENTECAVIR , -, VAY736

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  4. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  5. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  6. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  7. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  8. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  9. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  10. Deferasirox

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  11. Deferasirox granule formulation

    Novartis Pharmaceuticals

    Transfusion-dependent Anemia

    phase 2 small molecule completed

    1 trial

  12. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  13. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  14. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  15. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  16. EYU688

    Novartis Pharmaceuticals

    Dengue

    phase 2 small molecule active

    1 trial

  17. Eltrombopag

    Novartis Pharmaceuticals

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  18. FGF401

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  19. FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  20. FLUDARABINE PHOSPHATE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, BENDAMUSTINE, PHE885

    Novartis Pharmaceuticals

    Adult patients with relapsed and refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  21. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  22. FWY003, FWY003, Placebo to FWY003, FWY003

    Novartis Pharmaceuticals

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  23. GHZ339, -, Placebo to GHZ339, -, PIMECROLIMUS , TACROLIMUS , -

    Novartis Pharmaceuticals

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  24. GIA632

    Novartis Pharmaceuticals

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources